about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Ex­clu­sive: Vik Ba­jaj set out al­most 2 years ago to hatch new com­pa­nies that would shake up health­care with da­ta ...

5 years ago
Startups

Eli Lil­ly ax­es 163 Der­mi­ra staffers, shut­ters Men­lo Park site as it clos­es in around Dupix­ent ri­val le­brik­izum­ab

5 years ago
People
Pharma

An­ti-ag­ing biotech up­start plucks a drug from Am­gen's dis­card pile, piv­ot­ing from heart fail­ure to mus­cle con­di­tions

5 years ago
Deals

Eli Lil­ly seeds a well-con­nect­ed Chi­na neu­ro start­up with drugs aim­ing at where Bio­gen, Voy­ager missed

5 years ago
Deals
China

Tu­mor-treat­ing elec­tric fields show ear­ly promise in NSCLC — boost­ing both Novo­cure and its Chi­nese biotech part­ner

5 years ago
R&D

Amarin CEO John Thero pass­es ba­ton to Eu­rope com­mer­cial chief as M&A hopes con­tin­ue to de­flate

5 years ago
People

Covid-19 roundup: As­traZeneca's Farx­i­ga fails PhI­II test; Sup­ply deal for Eli Lil­ly's so­lo bam­lanivimab of­fi­cial­ly ...

5 years ago
Coronavirus

The End­points 20 un­der 40, biotech's new nor­mal, Stéphane Bancel's one re­gret, and more

5 years ago
Weekly

John Robin­son re­cruits a small band of Ar­ray vets to kick­start dis­cov­ery at Co­gent; Syn­tim­mune co-founder takes ...

5 years ago
Peer Review

MPM-backed Were­wolf, Mer­ck-part­nered Arti­va make quick IPO flip while Lu­ca Santarel­li's biotech rais­es $127.5M

5 years ago
Financing

Eye­ing stan­dard of care sta­tus in 3rd-line TNBC, Gilead nails down full OK for Trodelvy with a slight­ly broad­er la­bel

5 years ago
Pharma
FDA+

Covid-19 roundup: As­traZeneca paus­es vac­cine tri­al for chil­dren as blood clot probe con­tin­ues; EMA to in­ves­ti­gate ...

5 years ago
Coronavirus

FDA push­es eczema de­ci­sion for Eli Lil­ly's Olu­mi­ant, Pfiz­er's abroc­i­tinib back 3 months — rais­ing more ques­tions ...

5 years ago
Pharma
FDA+

As­traZeneca’s big ADC part­ner pledges to pour $13.6B in­to can­cer R&D over next 5 years — and En­her­tu looms large

5 years ago
Pharma

Hav­ing shipped its first bench­top gene edit­ing de­vices, In­scrip­ta draws an­oth­er $150M from deep in­vestor well

5 years ago
Financing

Take­da, CSL Behring fold big plas­ma al­liance af­ter PhI­II flop — join­ing a slew of an­ti­bod­ies that failed to help ...

5 years ago
R&D
Coronavirus

Leg­endary biotech leader pass­es away, re­newed ten­sion around ad­u­canum­ab, Mer­ck­'s rare de­feat, and more

5 years ago
Weekly

Covid-19 roundup: Emer­gen­t's er­ror costs J&J a vac­cine batch; Pfiz­er head says EU re­stric­tions slow vac­cine ...

5 years ago
Coronavirus
Manufacturing

Bet­ting ear­ly on an AI niche, RA Cap­i­tal seeds a young founder's quest to un­lock 'Holy Grail' tar­gets

5 years ago
Financing
Startups

Armed with Pfiz­er's ADC plat­form, Pyx­is scores $152M round to shoot for the clin­ic while tak­ing its time on I/O ...

5 years ago
Financing

Af­ter pi­lot project, Take­da inks $500M pact to tap in­to a Ke­van Shokat pro­tégé's co­va­lent small mol­e­cule fish­ing ...

5 years ago
Deals

Io­n­is un­veils pos­i­tive PhII da­ta for in-house rare dis­ease drug, paving way to block­buster ri­val­ry with Take­da

5 years ago
R&D

Bris­tol My­ers Squibb, blue­bird land once-high-stakes ap­proval on BC­MA CAR-T — and it bodes well for ri­val J&J

5 years ago
R&D

As­traZeneca's Covid-19 vac­cine woes, Mon­cef Slaoui re­signs over sex­u­al ha­rass­ment claims, FDA acts tough, and more

5 years ago
Weekly
First page Previous page 52535455565758 Next page Last page
A service from the Financial Times